

. News Releases

Major news releases during April - September 2006 are as below.

Please refer to our web site for details (<http://www.takeda.com/>).

Date	Summary
3-Apr-06	Takeda Enters into Joint Research Agreement with Arius on Functional Antibodies in Cancer Field
3-Apr-06	Takeda Submits New Drug Application for Extended Release Type 2 Diabetes Medication, ACTOplus met™(pioglitazone HCl and metformin HCl)
3-Apr-06	Transfer of Shares of Mitsui Takeda Chemicals, Inc. from Takeda to Mitsui Chemicals
20-Apr-06	Takeda Announces Conclusion of Successful ACTOS® (pioglitazone HCl) Marketing Collaboration in the United States
26-Apr-06	AMITIZA™(lubiprostone), the First Selective Chloride Channel Activator for the Treatment of Chronic Idiopathic Constipation, Launches in the United States <i>Novel mechanism of action provides effective and predictable relief for adults living with chronic idiopathic constipation</i>
11-May-06	Takeda Announces "2006-2010 Medium-Term Management Plan" - Growth toward a World-class Pharmaceutical Company with Japanese Origin -
11-May-06	Notice regarding Acquisition of the Company's own shares
11-May-06	Takeda to Change the Structure of Consolidated Subsidiaries, Daiwa Estate and Shinwa Estate by Stock-for-Stock Exchange, Corporate Demerger and Merger
6-Jun-06	Status of Initial Marketing Authorisation Application for Competact™ (pioglitazone/metformin) for Type 2 Diabetes in Europe
13-Jun-06	New Results from the Landmark PROactive Trial Found That ACTOS®(pioglitazone HCl) Reduced the Occurrence of Major Adverse Cardiovascular Events <i>Additional results showed ACTOS delayed the need for insulin use in high - risk patients with type 2 diabetes</i>
13-Jun-06	ACTOS® (pioglitazone HCl) To Be Studied In New Trial Investigating Its Effects On Atherosclerosis In Patients With Type 2 Diabetes <i>Study further examines possible cardiovascular effects of ACTOS beyond glycemic control</i>
13-Jun-06	Cephalon and Takeda Announce Agreement to Co-Promote PROVIGIL®in the United States <i>Agreement More Than Doubles Size of PROVIGIL Sales Force</i>
16-Jun-06	Additional Indication of Non-Erosive Reflux Disease Approved for Takepron® Capsules 15 and Takepron®OD Tablets 15
21-Jun-06	Notice of Execution of Acquisition of the Company's Own Shares
27-Jun-06	Takeda to Establish a New Company for European Sales & Marketing
28-Jun-06	Correction against Takeda Based on Transfer Pricing Taxation
10-Jul-06	Incidence of atrial fibrillation significantly reduced by Candesartan therapy in heart failure patients
10-Jul-06	Takeda and Galaxy Biotech Sign License Agreement for Galaxy's Investigational Antibodies for the Treatment of Cancer
11-Jul-06	Takeda's Investigational Compound TAK-491 for Treatment of Hypertension Enters into Phase 2 Clinical Stage in the U.S. and Europe
21-Jul-06	Start of Phase 3 Clinical Program in the U.S. of Fixed Dose Combination Product of Actos® + TAK-536 for Treatment of Patients with Type 2 Diabetes Associated with Hypertension
31-Jul-06	Takeda and BioNumerik Announce Results of Tavecept™ Phase 3 Trials Focused on Neuropathy Indication
31-Jul-06	Notice regarding Acquisition of the Company's own shares
3-Aug-06	Marketing Authorisation Granted for Competact™ (pioglitazone/metformin) for Type 2 Diabetes in Europe
4-Sep-06	New Analyses Show ACTOS®(pioglitazone HCl) Reduced Risk of Secondary Stroke by Almost 50 Percent in High Risk Type 2 Diabetes Patients
7-Sep-06	Discontinuation of Development of Anti-Diabetic Agent TAK-654
7-Sep-06	Notice of Execution of Acquisition of the Company's Own Shares
7-Sep-06	Notice regarding Acquisition of the Company's own shares
15-Sep-06	ACTOS® (pioglitazone HCl) Demonstrates Significant Improvements in Cardiovascular Outcomes for High-Risk Patients with Type 2 Diabetes <i>Results presented at the 42nd European Association for the Study of Diabetes Annual Meeting</i>
19-Sep-06	London Symphony Orchestra and Takeda Pharmaceutical Company launch the 7th Takeda Global Concert Series
25-Sep-06	Notice of Execution of Acquisition of the Company's Own Shares
28-Sep-06	Notice regarding Acquisition of the Company's own shares